ArticleNano letters2025
Targeting Intracellular miRNA in Different Cancer Cell Models Using Gold Nanoprobes and Combined Mass Cytometry and Single Particle ICP-MS.
Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quantitative Single-Cell Multielemental Analysis Using Metal-Loaded Microparticles: toward a Universal Quantification Workflow in Mass Cytometry.Analytical chemistry · 2026Article
- Sequential versus Simultaneous Quantitative Analysis of Biomarkers in Individual Cells by ICP-MS and Mass Cytometry: A Focus on Immunotherapy.Analytical chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA-conjugated gold nanoparticles (AuNPs) were developed to target intracellular miRNA-16-5p across various cancer cell models by base pair complementarity. The Au-nanoprobe uptake was addressed by multiparametric mass cytometry (CyTOF) monitoring iridium and gold, enabling discrimination among Au nanoprobes in intact cells and cellular debris. Our findings reveal significantly higher incorporation in lung cancer (A549) and melanoma (A375) cells compared to hepatic (HepG2) and ovarian (A2780) models with particle numbers ranging from 200 to 1 AuNPs per cell, respectively. The internalized Au nanoprobes targeting miR-16-5p were captured by mixing the lysed cells with a half-complementary DNA probe immobilized on streptavidin-coated magnetic microparticles. By counting the Au events in the captured solution is possible to quantitatively assess the concentration of miR-16-5p on each cell line. Together, these two complementary MS-based strategies establish a platform for the quantitative evaluation of nanocarrier-mediated miRNA targeting, offering new avenues for the development of miRNA-based cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.